Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Neuromuscular Blockade

Therapeutic area intelligence for Neuromuscular Blockade with 14 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 14
Catalysts: 0
Companies: 7

Companies

Mankind Pharma →

Assets

Sugammadex Sodium →

Recent signals(14)

August 1, 2026

Hikma's Sugammadex Sodium ANDA218727 Receives Approval Status

Hikma's ANDA for Sugammadex Sodium has received an approval status (AP) from the FDA.

CompetitiveAugust 1, 2026

Hikma's Sugammadex Sodium ANDA218728 Receives Abbreviated Approval

Hikma's ANDA218728 for Sugammadex Sodium has received Abbreviated Approval from the FDA.

StrategyAugust 1, 2026

FDA Grants Approval for Sugammadex Sodium (ANDA218814) by SteriScience

The FDA has granted approval for Sugammadex Sodium under application ANDA218814 submitted by SteriScience.

RegulatoryAugust 1, 2026

Teva's Sugammadex Sodium Receives FDA Approval Status

Teva Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Sugammadex Sodium.

StrategyAugust 1, 2026

FDA Grants Approval for Sugammadex Sodium ANDA219448 by Fresenius Kabi

The FDA has granted approval for the ANDA219448 application for Sugammadex Sodium submitted by Fresenius Kabi.

RegulatoryAugust 1, 2026

FDA Accepts Sugammadex Sodium Application from Mankind Pharma

The FDA has accepted the application for Sugammadex Sodium submitted by Mankind Pharma.

CompetitiveAugust 1, 2026

Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval

Reddy's has received FDA approval for Sugammadex Sodium under ANDA214236.

RegulatoryAugust 1, 2026

FDA Grants Approval for Sugammadex Sodium ANDA214306 by Zenara

The FDA has granted approval for the ANDA214306 application for Sugammadex Sodium submitted by Zenara.

StrategyAugust 1, 2026

Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)

Sandoz has received an Abbreviated New Drug Application (ANDA) approval for Sugammadex Sodium.

CompetitiveAugust 1, 2026

FDA Grants Approval for Sugammadex Sodium ANDA214319 by Sun Pharma

The FDA has granted approval for Sugammadex Sodium under application ANDA214319 submitted by Sun Pharma.

RegulatoryAugust 1, 2026

Mylan's Sugammadex Sodium ANDA213915 Receives AP Status from FDA

Mylan's ANDA for Sugammadex Sodium has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryAugust 1, 2026

Lupin's Sugammadex Sodium ANDA214338 Receives Approval Status

Lupin's ANDA214338 for Sugammadex Sodium has received an approval status of AP from the FDA.

RegulatoryAugust 1, 2026

FDA Grants Approval for Sugammadex Sodium under ANDA214368

The FDA has granted approval for Sugammadex Sodium under ANDA214368, submitted by MSN.

RegulatoryJuly 14, 2026

FDA Submission Update for Sugammadex by Tamarang SA

Tamarang SA has submitted an original ANDA for Sugammadex, currently under standard review.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.